Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.

@article{Stahl2013EffectivenessOL,
  title={Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.},
  author={Stephen M Stahl and Josephine B. Cucchiaro and Doreen Simonelli and Jay Hsu and Andrei Pikalov and Antony Loebel},
  journal={The Journal of clinical psychiatry},
  year={2013},
  volume={74 5},
  pages={
          507-15
        }
}
OBJECTIVE The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. METHOD Patients who completed a 6-week, double-blind, placebo-controlled study evaluating the efficacy of fixed doses of once-daily lurasidone (40 or 120 mg) or olanzapine 15 mg (to confirm assay sensitivity) were eligible to receive flexibly… 

Figures and Tables from this paper

Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
TLDR
In this 22-month, open-label extension study, treatment with lurasidone was associated with minimal effects on weight, glucose, lipids, and prolactin and patients demonstrated sustained improvement in the PANSS total score for up to 24 months of lurasIDone treatment.
Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
TLDR
In this 6-month, open-label extension study, treatment with lurasidone was generally well-tolerated with sustained improvement in efficacy measures observed in outpatients with schizophrenia or schizoaffective disorder who had switched to lurasidsone from a broad range of antipsychotic agents.
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
TLDR
Treatment with lurasidone 40 or 80 mg once daily (flexibly dosed) continued to be well tolerated with patients demonstrating further improvement in symptoms over the course of a 12-week open-label extension study in patients with schizophrenia.
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
TLDR
This multicenter, placebo-controlled, randomized withdrawal study demonstrated the efficacy of lurasidone for the maintenance treatment of patients with schizophrenia.
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
TLDR
None of the lurasidone groups separated from placebo in this clinical study of patients with acute schizophrenia, and haloperidol, which was included for assay sensitivity, did not separate from placebo, resulting in a failed study.
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
TLDR
In this 6-month extension study, lurasidone treatment was generally well-tolerated and associated with minimal effects on weight, metabolic parameters, and prolactin levels.
Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
TLDR
Efficacy outcomes were generally similar between groups during the DB trial, and were maintained during OLE, confirming lurasidone was generally well tolerated and effective in clinically stable schizophrenia patients over the long term.
Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
TLDR
Long-term cariprazine treatment at doses up to 9 mg/d appeared to be generally safe and well tolerated in patients with schizophrenia.
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
TLDR
A low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
TLDR
Treatment with both doses of lurasidone or with olanzapine was associated with significantly greater improvement at week 6 on Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive and negative subscale scores, and CGI-S score compared with placebo.
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
TLDR
In this study, which was limited by a relatively high discontinuation rate, lurasidone provided effective treatment for patients with acute exacerbation of chronic schizophrenia and had minimal effects on weight and metabolic parameters.
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
TLDR
Long-term treatment with lurasidone was generally well tolerated in this study, with minimal effects on weight and metabolic outcomes.
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
TLDR
There was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed and movement disorder rating scales did not demonstrate meaningful changes.
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
TLDR
The results of this study suggest that the novel psychotropic agent lurasidone is a safe and effective treatment for patients with an acute exacerbation of schizophrenia.
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
TLDR
It is suggested that outpatients who partially respond to conventional antipsychotics, risperidone, or olanzapine may experience improved control of psychotic symptoms following a switch to ziprasidone.
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
TLDR
Any of the three dosing strategies evaluated can be used safely for switching patients to aripiprazole from antipsychotic monotherapy, and patients' symptoms may continue to improve after switching to the drug.
Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone
TLDR
Clinically significant sustained improvements in weight, BMI, total cholesterol, and triglyceride levels were observed among patients switched to ziprasidone from risperidone or olanzapine.
...
1
2
3
4
...